On May 31, 2023, a registration certificate was received from the Russian Ministry of Health for the medical use of the drug AVIANDR® (INN: maritupirdine) for the treatment of generalized anxiety disorder and adjustment disorders, including those caused by COVID-19.

The effectiveness of the drug has been confirmed by extensive clinical studies. More than 1,900 people took part in randomized placebo-controlled studies. Clinical observations have demonstrated a significant improvement in the condition of patients, already in the first week of use, 40% of patients showed a decrease in symptoms; 50% decrease in anxiety in 89% of patients at 32 weeks of therapy; 68.8% of patients achieve remission on the 28th day of therapy. An important advantage is the absence of typical side effects: it does not cause drowsiness, emotional inhibition, withdrawal syndrome or decreased sexual desire, which is often encountered when taking other drugs. This significantly increases patient adherence to treatment and compliance with the prescribed regimen.

In 2025, Avineiro , a member of the ChemRar group of companies and the owner of the registration certificate for the drug AVIANDR®, announced that the active substance of the drug had been assigned an international non-proprietary name (INN) — maritupirdine. This is an official recognition of the uniqueness and innovativeness of the Russian molecule and its inclusion in the international pharmaceutical registry of the World Health Organization.